|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
ALTANA Pharma AG (AAA): Once-Daily Alvesco Provides Comparable Relief Of Asthma Symptoms To Twice-Daily Budesonide And Fluticasone
10/19/2005 5:13:04 PM
BAD HOMBURG, Germany--(BUSINESS WIRE)--March 21, 2005--ALTANA Pharma, the pharmaceutical group of ALTANA AG (NYSE:AAA; FWB:ALT), presented data during the American Academy of Allergy, Asthma and Immunology's (AAAAI) 61st annual meeting, demonstrating that once-daily Alvesco(R) (ciclesonide), a new inhaled corticosteroid for the treatment of asthma, is comparable to already marketed twice-daily inhaled corticosteroids, budesonide and fluticasone propionate.
"Often, patients will miss a dose of their asthma medication, which could increase the likelihood of serious asthma complications," noted principal investigator Professor H. Magnussen, Medical Director of the Centre of Pneumology and Thoracic Surgery in Grosshansdorf, Germany. "These findings are significant because they show that patients can control their symptoms with a once-daily inhalation like Alvesco, which may enhance compliance."
|
|
|
|
|
|
|
|
|
|
|